Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.81 |
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | HPGD | P15428 | 4/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | TOP2A | P11388 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | CASP9 | P55211 | 1/20 | 0.57 |
| ▸ | BAX | Q07812 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofloxacin SCHEMBL5617757 | 0.99 | KDM4E (0.82) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL5618787 | 0.98 | KDM4E (0.81) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL1230169 | 0.98 | KDM4E (0.81) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL3721756 | 0.98 | KDM4E (0.81) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL4459714 | 0.98 | KDM4E (0.81) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL1445074 | 0.98 | KDM4E (0.81) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL3134078 | 0.98 | KDM4E (0.81) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL22163790 | 0.91 | KDM4E (0.90) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL4459712 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2900 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121337-B | Phenoxyaromatic acid with cyclopropyl and pharmaceutically acceptable salt thereof, and preparation method and application thereof | 华创合成制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-113121337-A | Phenoxy aromatic acid with cyclopropyl and pharmaceutically acceptable salt thereof, and preparation method and application thereof | 华创合成制药股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| WO-2020133013-A1 | CRYSTALLINE FORM B OF CYPYRAFLUONE ISOPROPYLAMINE SALT, AND PREPARATION METHOD AND USE THEREFOR | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133017-A1 | CYPYRAFLUONE MONOISOPROPYLAMINE SALT CRYSTALLINE FORM F AND PREPARATION METHOD AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133021-A1 | CYPYRAFLUONE DIMETHYLAMINE SALT D CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133018-A1 | AMORPHOUS CICLOPIROX FLURIDONE DIMETHYLAMINE SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133019-A1 | CRYSTALLINE FORM B OF CYPYRAFLUONE DIMETHYLAMINE SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133011-A1 | AMORPHOUS CYPYRAFLUONE MONOISOPROPYLAMINE SALT AND PREPARATION METHOD AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133020-A1 | CYPYRAFLUONE DIMETHYLAMINE SALT C CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020133015-A1 | CYPYRAFLUONE MONOISOPROPYLAMINE SALT D CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0997466-A1 | Novel antimicrobial lactam-quinolones | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5656623-A | BACTERICIDES; ANTIBIOTICS | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-12 | — | — | US | disclosed |
| US-5648346-A | Antimicrobial carbacephem-quinolones | THE PROCTER & GAMBLE COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5646139-A | TREATING AND PREVENTING INFECTION | THE PROCTER & GAMBLE COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| US-5637580-A | ANTIBIOTICS | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0366189-A2 | Novel antimicrobial lactam-quinolones | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| US-4563459-A | FUNGICIDES AND BACTERICIDES FOR AGRICULTURAL USE | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | KDM4E 2995/4885ALDH1A1 1731/4885LMNA 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.